Primex Pharmaceuticals and POA Pharma sign a strategic partnership to commercialise OZALIN in the Nordic region
Gothenburg and Zug, 21st February 2019 – POA Pharma Scandinavia AB, a market-oriented Boutique Healthcare Company, working in close contact with healthcare organizations, professionals and hospitals in Nordic countries and Primex Pharmaceuticals AG, an innovative Anaesthesia pharmaceutical company, today announced a strategic agreement to launch OZALIN® in Denmark, Finland, Norway and Sweden.One of the challenges facing paediatric anaesthetists in treating children, either for premedication prior to surgery or during procedural sedation, is the lack of acceptable approved medications. An